Increasing Transparency in Generic Drug Applications Act

Increased Certainty for Applicants: The Secretary must inform a person whether a drug is qualitatively and quantitatively the same as the listed drug upon request or during the review process (Section 2(a)(i)). This provides clarity for those submitting abbreviated applications.

Detailed Disclosure of Discrepancies: If a drug is determined not to be the same as the listed drug, the Secretary is required to identify the specific ingredient causing the issue and the exact amount of any quantitative deviation (Section 2(a)(ii)). This ensures applicants know exactly why a drug does not match.

Consistency in Determinations: The Secretary cannot change or rescind a determination that a drug is the same as the listed drug unless there is a specific reason, such as a change in the listed drug's formulation due to safety or effectiveness, or a corrected error (Section 2(a)(iii)). This creates a more stable regulatory environment.

Standardized Guidance: The Secretary of Health and Human Services is required to issue guidance describing how they determine if a drug is qualitatively and quantitatively the same, including how to assess pH adjusters (Section 2(b)(1)).